Quick Take: ABBV - APGE acquisition - a super-derisked bolstering expansion in Atopic Derm.

Research evidence excerpt

Quick Take: ABBV - APGE acquisition - a super-derisked bolstering expansion in Atopic Derm.

Courtney Breen +1 917 344 8407 courtney.breen@bernsteinsg.com 22 June 2026

OVERVIEW

Apogee Therapeutics is a clinical-stage biotechnology company that advances its pipeline utilizing a development strategy of

"derisked science," targeting well-established, clinically-validated biological mechanisms rather than pursuing high-risk novel

pathways. By applying advanced antibody engineering techniques, such as YTE or LS amino acid modifications that optimize

neonatal Fc receptor (FcRn) binding and maximize antibody recycling, the company designs novel biologics with significantly

extended half-lives. This engineering approach delivers candidates optimized for half-life extension, improved formulation, and

high-yield, high-titer manufacturing to reduce injection frequency and lower cost of goods sold (COGS) at launch. Ultimately, the

company leverages a "pipeline-in-a-product" approach, seeking to validate doses in primary indications like atopic dermatitis or

asthma and then expand directly into other attractive indications such as COPD or eosinophilic esophagitis (EoE).

The lead candidate in Apogee's pipeline is zumilokibart (APG777), a subcutaneous monoclonal antibody targeting IL-13

that exhibits equivalent potency to lebrikizumab (Ebglyss) and dupilumab (DUPIXENT) but features an exceptionally long half-

life of approximately 75 to 77 days. This extended half-life supports a maintenance dosing schedule of every 3 to 6 months

(representing just 2 to 4 injections per year compared to 13 to 26 injections under current treatment paradigms) and is being

developed for moderate-to-severe atopic dermatitis (AD), asthma, and EoE. In May 2026, Apogee reported positive 16-